Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

78.04 -1.72 (-2.16%)
Streaming Delayed Price Updated: 11:29 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗
The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs. 
Via Investor's Business Daily
News headline image
This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗
Via Stocktwits
Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy ↗
Via Stocktwits
News headline image
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
News headline image
What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial ↗
Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data. 
Via Benzinga
News headline image
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗
FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements. 
Via Benzinga
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host investors and analysts for Innovation Day 2025
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here are the top movers in Tuesday's session. ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies ↗
In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗
Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events. 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. ↗
Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo. 
Via Investor's Business Daily
News headline image
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup ↗
IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern. 
Via Chartmill
News headline image
What's Going On With Takeda Stock On Friday? ↗
Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro. 
Via Benzinga
News headline image
Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
From Ionis Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.